Mohammadinejad, R., Ashrafizadeh, M., Pardakhty, A. et al. Nanotechnological Strategies for Osteoarthritis Diagnosis, Monitoring, Clinical Management, and Regenerative Medicine: Recent Advances and Future Opportunities. Curr Rheumatol Rep 22, 12 (2020). https://doi.org/10.1007/s11926-020-0884-z
Nanotechnological strategies for osteoarthritis diagnosis, monitoring, clinical management, and regenerative medicine : recent advances and future opportunities
|Author:||Mohammadinejad, Reza1; Ashrafizadeh, Milad2; Pardakhty, Abbas1;|
1Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
2Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran
3Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Santariskiu 5, LT-08406, Vilnius, Lithuania
4Microelectronics Research Unit, Faculty of Information Technology and Electrical Engineering, University of Oulu, PL 4500, 3FI-90014, Oulu, Finland
5Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland
6Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
7Centre for Sport, Exercise and Osteoarthritis Versus Arthritis, Queen’s Medical Centre, Nottingham, UK
8Sheik Salem Bin Mahfouz Scientific Chair for Treatment of Osteoarthritis with Stem Cells, King AbdulAziz University, Jeddah, Saudi Arabia
9University Medical Center Utrecht, Department of Orthopedics and Department of Rheumatology & Clinical Immunology, 508 GA, Utrecht, The Netherlands
|Online Access:||PDF Full Text (PDF, 0.6 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020060941239
|Publish Date:|| 2020-06-09
Purpose of Review: In this review article, we discuss the potential for employing nanotechnological strategies for the diagnosis, monitoring, and clinical management of osteoarthritis (OA) and explore how nanotechnology is being integrated rapidly into regenerative medicine for OA and related osteoarticular disorders.
Recent Findings: We review recent advances in this rapidly emerging field and discuss future opportunities for innovations in enhanced diagnosis, prognosis, and treatment of OA and other osteoarticular disorders, the smart delivery of drugs and biological agents, and the development of biomimetic regenerative platforms to support cell and gene therapies for arresting OA and promoting cartilage and bone repair.
Summary: Nanotubes, magnetic nanoparticles, and other nanotechnology-based drug and gene delivery systems may be used for targeting molecular pathways and pathogenic mechanisms involved in OA development. Nanocomposites are also being explored as potential tools for promoting cartilage repair. Nanotechnology platforms may be combined with cell, gene, and biological therapies for the development of a new generation of future OA therapeutics.
Current rheumatology reports
|Type of Publication:||
A2 Review article in a scientific journal
|Field of Science:||
216 Materials engineering
217 Medical engineering
The research underpinning some of the work presented has received funding from a number of sources including The European Commission Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases) and the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115770, resources of which are composed of financial contribution from the European Union’s Seventh Framework programme (FP7/2007–2013), EFPIA companies’ in-kind contribution and the H2020 projects RESTORE (project number 814558; topic NMBP-22-2018 RIA), and MIRACLE (project number 780598; topic ICT-30-2017). Details of the D-BOARD FP7 Consortium are available at: http://www.d-board.eu. Details of the APPROACH IMI Consortium are available at https://www.approachproject.eu. Details of the H2020-RESTORE Consortium are available at restoreproject.eu. Details on the H2020-MIRACLE Consortium are available at miracleproject.eu. A.M. received funding from the European Commission through a Marie Curie Intra-European Fellowship for Career Development grant (project number 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF) and financial support from the European Structural and Social Funds through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the activity “Improvement of researchers” qualification by implementing world-class R&D projects” of Measure No. 09.3.3-LMT-K-712 (grant application code: 09.3.3-LMT-K-712-01-0157, agreement No. DOTSUT-215). A.M., E. B, I. U, and J. D also received financial support from the European Structural and Social Funds through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the Programme “Attracting Foreign Researchers for Research Implementation,” Grant No. 0.2.2-LMT-K-718-02-0022. Open access funding provided by University of Oulu including Oulu University Hospital.
© The Authors 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.